Paromomycin - PharmaKB

Paromomycin

Paromomycin (paromomycin) is a small molecule pharmaceutical. Paromomycin was first approved as Humatin on 1982-01-01. It is used to treat amebiasis, cryptosporidiosis, and protozoan infections in the USA.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
infections	D007239
digestive system diseases	D004066
animal diseases	D000820

Trade Name

FDA

EMA

Paromomycin (discontinued: Humatin, Paromomycin)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

No data

Labels

FDA

EMA

Brand Name	Status	Last Update
care science essential first aid	C200263	2024-08-29
care science osha first aid	C200263	2024-02-05
emergency preparedness	OTC monograph final	2010-06-02
good neighbor pharmacy emergency preparedness and first aid contains 167 pieces	OTC monograph final	2010-06-11
humatin	ANDA	2023-01-10
madecassol	unapproved drug other	2019-11-08
paromomycin sulfate	ANDA	2017-11-07

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
cryptosporidiosis	—	D003457	A07.2
protozoan infections	—	D011528	B50-B64
amebiasis	EFO_0007144	D000562	A06

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

A: Alimentary tract and metabolism drugs

— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents

— A07A: Intestinal antiinfectives

— A07AA: Antibiotics, intestinal

— A07AA06: Paromomycin

HCPCS

No data

Clinical

Clinical Trials

404 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hiv infections	D015658	EFO_0000764	B20	6	17	27	8	6	60
Leishmaniasis	D007896	EFO_0005044	B55	1	12	11	1	4	27
Healthy volunteers/patients	—	—	—	14	1	1	3	2	20
Tuberculosis	D014376	EFO_0000774	A15-A19	2	10	3	2	4	20
Infections	D007239	EFO_0000544	—	—	5	4	1	8	18
Acquired immunodeficiency syndrome	D000163	EFO_0000765	B20	2	1	9	1	2	15
Visceral leishmaniasis	D007898	—	B55.0	—	2	7	1	2	12
Communicable diseases	D003141	—	—	—	3	2	1	5	11
Hiv	D006678	—	—	1	2	3	3	2	10
Syndrome	D013577	—	—	4	6	—	1	2	10

Show 46 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Lymphoma	D008223	—	C85.9	12	19	10	—	—	36
Leukemia	D007938	—	C95	8	15	2	—	3	26
Large b-cell lymphoma diffuse	D016403	—	C83.3	7	9	7	—	—	19
B-cell lymphoma	D016393	—	—	8	8	5	—	—	18
Cutaneous leishmaniasis	D016773	—	B55.1	1	10	4	—	2	15
Hepatitis c	D006526	—	B19.2	2	8	3	—	1	13
Hepatitis	D006505	HP_0012115	K75.9	2	8	2	—	1	12
Chronic hepatitis c	D019698	EFO_0004220	B18.2	1	8	2	—	1	11
Immunologic deficiency syndromes	D007153	HP_0002721	D84.9	2	1	6	—	1	10
Lymphoid leukemia	D007945	—	C91	2	5	2	—	1	10

Show 45 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Myeloid leukemia	D007951	—	C92	6	8	—	—	1	13
Myelodysplastic syndromes	D009190	—	D46	4	9	—	—	—	11
Myeloid leukemia acute	D015470	—	C92.0	5	6	—	—	—	10
Preleukemia	D011289	—	—	4	7	—	—	—	9
Neoplasms	D009369	—	C80	5	4	—	—	1	9
Fibrosis	D005355	—	—	1	4	—	—	3	7
Non-hodgkin lymphoma	D008228	—	C85.9	4	5	—	—	—	7
Precursor cell lymphoblastic leukemia-lymphoma	D054198	—	—	—	5	—	—	1	6
Chronic hepatitis b	D019694	EFO_0004239	B18.1	1	6	—	—	—	6
Bcr-abl positive chronic myelogenous leukemia	D015464	EFO_0000340	—	1	4	—	—	1	5

Show 89 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Chronic renal insufficiency	D051436	—	N18	1	—	—	—	1	2
Myelomonocytic leukemia acute	D015479	—	C92.5	1	—	—	—	1	2
Amyotrophic lateral sclerosis	D000690	HP_0007354	G12.21	2	—	—	—	—	2
Motor neuron disease	D016472	EFO_0003782	G12.2	2	—	—	—	—	2
Sclerosis	D012598	—	—	1	—	—	—	1	2
Osteomyelitis	D010019	EFO_0003102	M86	1	—	—	—	—	1
Hairy cell leukemia	D007943	—	C91.4	1	—	—	—	—	1
Precancerous conditions	D011230	—	—	1	—	—	—	—	1
Oral leukoplakia	D007972	—	K13.21	1	—	—	—	—	1
Leukoplakia	D007971	HP_0002745	—	1	—	—	—	—	1

Show 13 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hypercapnia	D006935	—	—	—	—	—	—	4	4
Inflammation	D007249	MP_0001845	—	—	—	—	—	3	3
Apnea	D001049	HP_0002104	R06.81	—	—	—	—	3	3
Bronchiectasis	D001987	HP_0002110	J47	—	—	—	—	2	2
Dermatitis	D003872	HP_0011123	L30.9	—	—	—	—	2	2
Postoperative nausea and vomiting	D020250	EFO_0004888	—	—	—	—	—	2	2
Hypercholesterolemia	D006937	HP_0003124	—	—	—	—	—	2	2
Autistic disorder	D001321	HP_0000717	F84.0	—	—	—	—	2	2
Autism spectrum disorder	D000067877	HP_0000729	F84.0	—	—	—	—	2	2
Respiratory distress syndrome	D012128	EFO_1000637	J80	—	—	—	—	2	2

Show 95 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Paromomycin
INN	paromomycin
Description	Paromomycin sulfate is an aminoglycoside sulfate salt resulting from the treatment of paromomycin with sulfuric acid. A broad-spectrum antibiotic, it is used for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis. It has a role as an antibacterial drug, an antiprotozoal drug, an anthelminthic drug and an antiparasitic agent. It is functionally related to a paromomycin.
Classification	Small molecule
Drug class	antibiotics (Streptomyces strain)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O